Ingredients by Nature (IBN), a supplier of science-backed citrus-derived flavonoids and ingredients, has announced approval by the US Patent and Trademark Office of a patent for IBN’s use of eriocitrin in its ingredient formulations, such as is found in Eriomin.
The eriocitrin patent claim is stated as “A method of reducing blood glucose levels in a human subject in need thereof, comprising administering to the subject a composition comprising 100-200 mg eriocitrin once per day.”
The patent will be officially issued in two to three months and published with its accompanying patent number.
“We couldn’t be happier with the progress we have made to recognise eriocitrin as a viable option for better health,” said Rob Brewster, president of IBN. “Supported by a successful first clinical trial and now this patent, our line of Eriomin lemon flavonoid blends, which are primarily comprised of eriocitrin, provide powerful support to managing healthy blood glucose levels. We look forward to revealing additional significant results from ongoing research into the effect that eriocitrin can have on blood glucose levels later this year.”
Two versions of Eriomin are currently available, Eriomin Glucose for prediabetes management and Eriomin Esport for a healthy gaming lifestyle, which help maintain blood glucose levels within the normal range.